Ironwood Pharmaceuticals' (IRWD) shares rose 9% in premarket trading on Friday as the company raised its adjusted core earnings guidance to greater than $105 million for 2025.

Reports Q1 revenue $8.12B, consensus $8.16B. “We had a consistent start to the year, aligned with our objectives for 2025. We are seeing good ...

Narrows FY25 free cash flow view to $17.5B-$18.0B from $17.3B-$18.0B. Affirms FY25 postpaid net customer additions of 5.5M-6.0M.Stay Ahead of ...

Discover key insights from Darling Ingredients' Q1 2025 earnings call. Learn about EBITDA guidance, renewable fuel strategies, and market resilience.